Inflammation is associated with voriconazole trough concentrations

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7098-7101

  Van Wanrooy, Marjolijn J P ^a   Span, Lambert F R ^a   Rodgers, Michael G G ^a   Van Heuvel, Edwin R Den ^a   Uges, Donald R A ^a   Van Werf, Tjip S Der ^a   Kosterink, Jos G W ^a,b   Alffenaara, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; ESOMEPRAZOLE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; OMEPRAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; SEX DIFFERENCE; STEADY STATE; TROUGH CONCENTRATION; AGE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOOD; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AGE FACTORS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; C-REACTIVE PROTEIN; DRUG MONITORING; FEMALE; HUMANS; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; VORICONAZOLE;

EID: 84912124222     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03820-14     Document Type: Article

References (27)

1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. http://dx.doi.org/10.1086/525258.
2. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. 2012. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:4793-4799. http://dx .doi.org/10.1128/AAC.00626-12.
3. Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS. 2012. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin. Infect. Dis. 55: 1080-1087. http://dx.doi.org/10.1093/cid/cis599.
4. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572. http://dx.doi.org/10.1128/AAC .50.4.1570-1572.2006.
5. Miyakis S, van Hal SJ, Ray J, Marriott D. 2010. Voriconazole concentrations and outcome of invasive fungal infections. Clin. Microbiol. Infect. 16:927-933. http://dx.doi.org/10.1111/j.1469-0691.2009.02990.x.
6. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. http://dx.doi.org/10.1086/524669.
7. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O. 2012. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokineticsbased analysis of adult patients with invasive fungal infections. Clin. Infect. Dis. 55:381-390. http://dx.doi.org/10.1093/cid/cis437.
8. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J. 2005. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 35:509-513. http://dx.doi.org/10.1038/sj.bmt.1704828.
9. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. 2009. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob. Agents Chemother. 53:1793-1796. http://dx.doi.org/1128/AAC.01316-08.
10. Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. 2009. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 49:196-204. http://dx.doi.org/10.1177 /0091270008327537.
11. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. 2003. Voriconazole. Clin. Ther. 25:1321-1381. http://dx.doi.org/10.1016/S0149-2918(03)80126-1.
12. Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48:1441-1458. http://dx.doi.org/10.1086/598327.
13. Morgan ET. 1997. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. 29:1129-1188. http://dx.doi.org/10.3109 /03602539709002246.
14. Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663. http://dx.doi.org/10.2165/00003088-200645070-00002.
15. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. 2003. The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56(Suppl 1):S2-S9. http://dx.doi.org/10.1046/j.1365-2125.2003.01992.x.
16. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl 1):S10-S16. http://dx.doi.org/10 .1046/j.1365-2125.2003.01993.x.
17. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. 2002. Pharmacokinetics and safety of voriconazole following intrave-nous-to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46: 2546-2553. http://dx.doi.org/10.1128/AAC.46.8.2546-2553.2002.
18. Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. 2010. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 878: 39-44. http://dx.doi.org/10 .1016/j.jchromb.2009.11.017.
19. Manian FA. 1995. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin. Infect. Dis. 21:114-121. http://dx.doi.org/10.1093/clinids/21.1.114.
20. Clyne B, Olshaker JS. 1999. The C-reactive protein. J. Emerg. Med. 17:1019-1025. http://dx.doi.org/10.1016/S0736-4679(99)00135-3.
21. Aitken AE, Morgan ET. 2007. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos. 35:1687-1693. http://dx.doi.org/10 .1124/dmd.107.015511.
22. Aitken AE, Richardson TA, Morgan ET. 2006. Regulation of drugmetabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46:123-149. http://dx.doi.org/10.1146/annurev.pharmtox.46 .120604.141059.
23. Renton KW. 2004. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr. Drug Metab. 5:235-243. http://dx.doi.org/10.2174/1389200043335559.
24. Moriyama B, Elinoff J, Danner RL, Gea-Banacloche J, Pennick G, Rinaldi MG, Walsh TJ. 2009. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob. Agents Chemother. 53:1712-1714. http://dx.doi.org/10.1128/AAC.01221-08.
25. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741. http://dx.doi.org/10.1124/dmd.31.6.731.
26. Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, Jonkman JH. 1999. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral con-traceptive-related gender differences. Eur. J. Clin. Pharmacol. 55:177-184. http://dx.doi.org/10.1007/s002280050615.
27. Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:448-454. http://dx.doi .org/10.1056/NEJM199902113400607.